
Charles River Laboratories
CRL · NYSE · Healthcare / Diagnostics & Research
Price History
Full chartMarket Stats
About
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services; and engages in development and production of cell therapies. The Discovery and Safety Assessment segment offers in vitro and in vivo discovery services for the discovery, development, and safety testing of novel drugs, molecule compounds, oligonucleotides, and biotherapeutics, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services; and vivarium space services. The Manufacturing Solutions segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products; offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and contract development and manufacturing products and services. The company has strategic collaborations with Parker Institute for Cancer Immunotherapy and Children's Hospital Los Angeles across its contract development and manufacturing organization; and Medigen Vaccine Biologics Corp for developing next-generation multivalent enterovirus vaccine, enhance global regulatory readiness, and support IND-enabling non-clinical studies. Additionally, it has a strategic alliance with Francis Crick Institute (Crick), Inc. for the development of Antibody-Drug Conjugate (ADC) drug discovery and de
Company Details
- SectorHealthcare
- IndustryDiagnostics & Research
- CEOMs. Birgit Girshick
- Employees18.30K
- Headquarters251 Ballardvale Street, Wilmington, MA, United States, 01887, USA
- Websitehttps://www.criver.com
Leadership
- Ms. Birgit GirshickCEO & Director · b. 1970
- Mr. Michael Gunnar KnellCorporate Senior VP & Chief Accounting Officer · b. 1977
- Mr. Joseph W. LaPlume J.D.Corporate Executive Vice President of Corporate Development & Strategy · b. 1974
- Ms. Victoria L. CreamerCorporate Executive VP & Chief People Officer · b. 1970
- Mr. Glenn G. Coleman CPACorporate Executive VP & CFO · b. 1968
- Mr. Mark MintzCorporate EVP, Chief Information Officer & Global Shared Services · b. 1974
- Mr. Todd SpencerCorporate Vice President of Investor Relations
- Ms. Kerry DaileyCorporate Senior VP & Chief Legal Officer
- Ms. Amy E. CianciarusoCorporate Senior Vice President, Chief Communications Officer & Government Relations
- Dr. Brian F. Bathgate Ph.D.Corporate Senior Vice President of European Safety Assessment · b. 1960
Financials
Income Statement
Balance Sheet
Cash Flow
Earnings
Key Statistics & Ratios
Analyst Ratings
- Strong Buy4
- Hold14
- Strong Sell1
Ownership Breakdown
- Institutions
- 123.67%
- Insiders
- 0.47%
- Retail / Other
- 0.00%
Top Institutional Holders
- BlackRock Inc3.86M8.08%
- FMR Inc3.46M7.24%
- Vanguard Capital Management, LLC3.20M6.71%
- Amvescap Plc.2.40M5.02%
- Vanguard Portfolio Management, LLC2.29M4.81%
- Harris Associates L.P.2.24M4.69%
- Allspring Global Investments Holdings, LLC1.91M3.99%
- State Street Corp1.87M3.92%
- Dimensional Fund Advisors, Inc.1.65M3.45%
- Ariel Investments, LLC1.51M3.15%
- Geode Capital Management, LLC1.31M2.74%
- Wellington Management Company LLP1.29M2.70%
- Citadel Advisors Llc1.19M2.50%
- Bank of America Corp1.14M2.38%
- T. Rowe Price Associates, Inc.1.13M2.36%
- Ameriprise Financial Inc1.11M2.32%
Top Fund Holders
- Fidelity Contrafund1.83M3.82%
- Vanguard MStar Total Stk Mkt Idx Invest1.53M3.21%
- Oakmark Select Investor1.50M3.14%
- Vanguard 500 Index Investor1.28M2.68%